Data as of Aug 22
| +0.59 / +3.83%|
The 8 analysts offering 12-month price forecasts for Durata Therapeutics Inc have a median target of 22.50, with a high estimate of 26.00 and a low estimate of 12.00. The median estimate represents a +40.63% increase from the last price of 16.00.
The current consensus among 9 polled investment analysts is to Buy stock in Durata Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.